The initial phase of an insect's innate immune response to foreign pathogens is triggered by the identification of exogenous invaders, a mechanism facilitated by pattern recognition receptors. Among these receptors, peptidoglycan recognition proteins (PGRPs), abundant in insects, are essential components of the innate immune system. The roles of PGRPs have been extensively elucidated in ; however, the mechanism underlying the immune response of to pathogens is unclear. Herein, we successfully cloned the full-length cDNA of a PGRP gene from , designated as the gene. The open reading frame of encodes 203 amino acids, including a secretion signal peptide and a canonical PGRP conserved domain. Multisequence alignment revealed that AaPGRP-LB possesses the amino acid residues essential for zinc binding and amidase activity. Molecular docking studies demonstrated that AaPGRP-LB exhibits a strong binding affinity for DAP-type and LYS-type peptidoglycan. The mRNA expression level of the gene significantly increased after oral infection with or . The purified recombinant AaPGRP-LB (rAaPGRP-LB) exhibited strong agglutination properties and demonstrated significant antimicrobial efficacy against and in the presence of zinc ions. This study highlights the critical role of AaPGRP-LB in the immune response of . These findings provide a foundation for future research on mosquito immune pathways for innovative vector control and disease prevention strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3390/ijms26052188 | DOI Listing |
Crit Care Explor
March 2025
Center for Experimental and Molecular Medicine, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Importance: Sepsis-related host-response anomalies contribute to acute kidney injury (AKI) duration. Data on the host-response specific to COVID-19-associated AKI (COVID-AKI) in critically ill patients is limited.
Objectives: We postulated that persistent COVID-AKI (> 48 hr) differs in host response from transient (< 48 hr) or no COVID-AKI.
J Drug Target
March 2025
School of Laboratory Animal & Shandong Laboratory Animal Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide, characterized by its complex pathogenesis and poor therapeutic outcomes. Despite recent advances in targeted molecular therapies, immune checkpoint inhibitors (ICIs), radiotherapy, and conventional chemotherapy, the five-year survival rate for this neoplasm remains dismally low. The progress in nanotechnology has revolutionized cancer treatment in recent years.
View Article and Find Full Text PDFJ Exp Med
June 2025
Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA.
To distinguish pathogens from commensals, the intestinal epithelium employs cytosolic innate immune sensors. Activation of the NAIP-NLRC4 inflammasome initiates extrusion of infected intestinal epithelial cells (IEC) upon cytosolic bacterial sensing. We previously reported that activation of the inflammasome in tuft cells, which are primarily known for their role in parasitic infections, leads to the release of prostaglandin D2 (PGD2).
View Article and Find Full Text PDFJ Med Microbiol
March 2025
Zoonosis Science Center, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
The global spread of extended-spectrum cephalosporinase-producing (producing extended-spectrum -lactamase or plasmid-borne AmpC, hereafter ESC-Ec) is a major public health concern. Whilst extensively studied in high-income countries, the transmission pathways between humans and animals in low- and middle-income countries (LMICs) remain unclear. In rural Cambodia, the asymptomatic carriage and transmission dynamics of ESC-Ec between humans and animals living in close proximity are poorly understood, highlighting the need for targeted research in this area.
View Article and Find Full Text PDFInt J Cancer
March 2025
College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
The use of Immune checkpoint inhibitors (ICIs) as monotherapy for patients with hepatocellular carcinoma (HCC) has been associated with an increased risk of hyperprogressive disease (HPD), the occurrence of which carries a poor prognosis. However, it is unknown whether contemporary frontline treatment with the combination of atezolizumab and bevacizumab causes significant HPD. This study conducted a secondary analysis of patient-level data from the IMbrave150 randomized controlled trial of atezolizumab plus bevacizumab versus sorafenib for frontline treatment of HCC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!